E-ISSN: 2619-9467

Contents    Cover    Publication Date: 28 Jun 2024
Year 2024 - Volume 34 - Issue 2

Open Access

Peer Reviewed

94 Viewed108 Downloaded

Incidentally Detected Uterine Sarcomas in Patients Operated with Myoma Uteri in a Tertiary Center: Retrospective Cohort Study

Full Text PDF  
JCOG. 2024;34(2):55-9
DOI: 10.5336/jcog.2023-100839
Article Language: EN
Copyright Ⓒ 2020 by Türkiye Klinikleri. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Objective: To estimate the incidence and report the details of hystological, clinical, surgical, and demographic features of incidental uterine sarcomas in patients operated with symptomatic myoma uteri. Material and Methods: We designed a retrospective cohort study at Adnan Menderes University Gynecologic Oncology Department that includes totally 896 patients with symptomatic myoma uteri who were operated as a hysterectomy or myomectomy. Following the definition of inclusion and exlusion criterias, incidental uterine sarcoma cases were detailed as histological subtype, tumor diameter, morcellation or fragmentation status in surgery, adjuvant treatment, recurrences, and survival. All cases were reported as a table without specific statistical analyzes. Results: A total of 775 hysterectomy and 121 myomectomy cases were analyzed. Fourteen sarcoma cases were reported. Two sarcoma cases were excluded due to adnexal sarcoma in final pathology. Ten cases were reported in final pathology incidentally. 7/10 cases were reported as leiomyosarcoma while low grade endometrial stromal sarcoma were reported in 2 cases. While all recurrences were seen in leiomyosarcoma group (5 cases), two of them died with disease-related complications. Conclusion: Studies have shown that uterine sarcomas are malignancies that are extremely rare and cannot be predicted preoperatively. Due to its low incidence and uncertain tumor behavior, in low-risk patients, myomectomy with mechanical or power morcellation is a safe surgical option when it is perfomed without abdominal spillage which can be common in laparoscopic surgery.
  1. Wright JD, Herzog TJ, Tsui J, Ananth CV, Lewin SN, Lu YS, et al. Nationwide trends in the performance of inpatient hysterectomy in the United States. Obstet Gynecol. 2013;122(2 Pt 1):233-41. [Crossref]  [PubMed]  [PMC] 
  2. Stewart EA, Nicholson WK, Bradley L, Borah BJ. The burden of uterine fibroids for African-American women: results of a national survey. J Womens Health (Larchmt). 2013;22(10):807-16. [Crossref]  [PubMed]  [PMC] 
  3. George S, Barysauskas C, Serrano C, Oduyebo T, Rauh-Hain JA, Del Carmen MG, et al. Retrospective cohort study evaluating the impact of intraperitoneal morcellation on outcomes of localized uterine leiomyosarcoma. Cancer. 2014;120(20):3154-8. [Crossref]  [PubMed] 
  4. Tropé CG, Abeler VM, Kristensen GB. Diagnosis and treatment of sarcoma of the uterus. A review. Acta Oncol. 2012;51(6):694-705. [Crossref]  [PubMed] 
  5. Food and Drug Administration. Quantitative assessment of the prevalence of unsuspected uterine sarcoma in women undergoing treatment of uterine fibroids. Accessed: 23.06.24. Available at: [Link] 
  6. AAGL Advancing Minimally Invasive Gynecology Worldwide. AAGL practice report: Morcellation during uterine tissue extraction. J Minim Invasive Gynecol. 2014;21(4):517-30. [Crossref]  [PubMed] 
  7. Tulandi T, Ferenczy A. Biopsy of uterine leiomyomata and frozen sections before laparoscopic morcellation. J Minim Invasive Gynecol. 2014;21(5):963-6. [Crossref]  [PubMed] 
  8. Multinu F, Casarin J, Tortorella L, Huang Y, Weaver A, Angioni S, et al. Incidence of sarcoma in patients undergoing hysterectomy for benign indications: a population-based study. Am J Obstet Gynecol. 2019;220(2):179.e1-179.e10. [Crossref]  [PubMed]  [PMC] 
  9. Mahnert N, Morgan D, Campbell D, Johnston C, As-Sanie S. Unexpected gynecologic malignancy diagnosed after hysterectomy performed for benign indications. Obstet Gynecol. 2015;125(2):397-405. [Crossref]  [PubMed] 
  10. Kho KA, Lin K, Hechanova M, Richardson DL. Risk of Occult Uterine Sarcoma in Women Undergoing Hysterectomy for Benign Indications. Obstet Gynecol. 2016;127(3):468-73. Erratum in: Obstet Gynecol. 2016;127(5):968. [Crossref]  [PubMed]  [PMC] 
  11. Brohl AS, Li L, Andikyan V, Običan SG, Cioffi A, Hao K, et al. Age-stratified risk of unexpected uterine sarcoma following surgery for presumed benign leiomyoma. Oncologist. 2015;20(4):433-9. [Crossref]  [PubMed]  [PMC] 
  12. Zhang J, Zhang J, Dai Y, Zhu L, Lang J, Leng J. Clinical characteristics and management experience of unexpected uterine sarcoma after myomectomy. Int J Gynaecol Obstet. 2015;130(2):195-9. [Crossref]  [PubMed] 
  13. Gao Y, Meng H, Zhang Y, Jiao T, Hui N. Retrospective analysis of 80 cases with uterine carcinosarcoma, leiomyosarcoma and endometrial stromal sarcoma in China, 1988-2007. Int J Clin Exp Pathol. 2014;7(4):1616-24. [PubMed]  [PMC] 
  14. D'Angelo E, Prat J. Uterine sarcomas: a review. Gynecol Oncol. 2010;116(1):131-9. [Crossref]  [PubMed] 
  15. Raine-Bennett T, Tucker LY, Zaritsky E, Littell RD, Palen T, Neugebauer R, et al. Occult Uterine Sarcoma and Leiomyosarcoma: Incidence of and Survival Associated With Morcellation. Obstet Gynecol. 2016;127(1):29-39. Erratum in: Obstet Gynecol. 2016;127(2):405. [Crossref]  [PubMed] 
  16. Steiner RA, Wight E, Tadir Y, Haller U. Electrical cutting device for laparoscopic removal of tissue from the abdominal cavity. Obstet Gynecol. 1993;81(3):471-4. [PubMed] 
  17. Pritts EA. The prevalence of occult leiomyosarcoma in women undergoing presumed fibroid surgery and outcomes after morcellation. Curr Opin Obstet Gynecol. 2018;30(1):81-8. [Crossref]  [PubMed] 
  18. van den Haak L, de Kroon CD, Warmerdam MI, Siebers AG, Rhemrev JP, Nieboer TE, et al. Incidence and groups at risk for unexpected uterine leiomyosarcoma: a Dutch nationwide cohort study. Arch Gynecol Obstet. 2019;299(1):159-65. [Crossref]  [PubMed]  [PMC]